| 摘要 |
The use of anti-C5 antibodies to reduce the dysfunction of the immune and hemostatic systems associated with extracorporeal circulation procedures, such as, cardiopulmonary bypass procedures, is disclosed. The antibodies have been found to significantly reduce complement activation, platelet activation, leukocyte activation, and platelet-leukocyte adhesion associated with such procedures. |
